China Medical System Holdings Limited China Medical System Holdings Limited

China Medical System Holdings Limited

0867

Rang in aandelen #4730
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Aandeelprijs
$1.31
Marktkapitalisatie
$3.18B
Verandering (1 dag)
-1.63%
Verandering (1 jaar)
-23.03%
Land
HK
Handel China Medical System Holdings Limited (0867)

Categorie

Healthcare
Omzet van China Medical System Holdings Limited (0867)
Omzet in Jun 2026 TTM: $1.25B
Volgens de laatste financiële rapporten van China Medical System Holdings Limited bedraagt de huidige omzet van het bedrijf (TTM) $1.25B. In 2023 behaalde het bedrijf een omzet van $1.13B een daling ten opzichte van de omzet in het jaar 2022, die $1.33B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van China Medical System Holdings Limited van 2006 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
2026 (TTM) $1.25B 22.48%
2024 $1.02B -9.61%
2023 $1.13B -14.66%
2022 $1.33B 1.13%
2021 $1.31B 23.37%
2020 $1.06B 21.90%
2019 $872.23M 10.42%
2018 $789.91M -3.92%
2017 $822.11M 16.47%
2016 $705.87M 29.00%
2015 $547.21M 15.08%
2014 $475.48M 31.01%
2013 $362.92M 28.63%
2012 $282.14M 34.51%
2011 $209.75M 57.92%
2010 $132.82M 37.69%
2009 $96.46M 32.86%
2008 $72.60M 40.24%
2007 $51.77M 37.69%
2006 $37.60M 0.00%
Omzet van vergelijkbare bedrijven of concurrenten